NCT04175444

Brief Summary

The goal of this study is to determine reference values of the VisuALL Field Test in pediatric population. Standard Automatic Perimetry (SAP) is the gold standard test for the evaluation of different diseases of the visual pathway like glaucoma. Its main goal is to measure the differential light sensitivity at several locations in the central field of vision. Nevertheless, the accuracy of the current devices is limited by several factors such as the inherent inconsistency of the psychophysical test, stressful examinations and frequency of testing. Several devices have been developed since the advent of the Octopus Perimeter and the Humphrey Field Analyzer (HFA) in an effort to improve the early detection of glaucoma. Several of these visual field test variants are implemented using laptops, iPads, and virtual reality headsets. These modalities bring portability but lack fixation methods, environmental control, and hardware standardization. These deficiencies may limit their wide usage. The main goal of this study is to develop an initial pediatric reference database of a novel visual field test ecosystem that takes advantage of a Head Mounted Device (HMD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 25, 2019

Completed
7 months until next milestone

Study Start

First participant enrolled

June 15, 2020

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2020

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

August 29, 2023

Status Verified

August 1, 2023

Enrollment Period

16 days

First QC Date

November 18, 2019

Last Update Submit

August 28, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Retinal sensitivity

    Retinal sensitivity at each location and compared between the two test strategies

    End of the recruitment phase, average 3 months

  • Mean retinal sensitivity

    Mean retinal sensitivity at each quadrants and each hemifield

    End of the recruitment phase, average 3 months

Secondary Outcomes (2)

  • Frequency of seeing curves

    End of the recruitment phase, average 3 months

  • Ease of device use

    End of the recruitment phase, average 3 months

Study Arms (1)

Normal Subjects

This is a study of normal subjects to establish a normative database.

Diagnostic Test: VisuALL Field AnalyzerDiagnostic Test: Humphrey Field Analyzer

Interventions

VisuALL Field AnalyzerDIAGNOSTIC_TEST

Each participant will conduct a visual field test with the visuaALL headset.

Also known as: visual field testing strategy, head mounted device, Olleyes
Normal Subjects

Each participant will conduct a standard of care Humphrey Visual Field.

Also known as: standard of care visual field test
Normal Subjects

Eligibility Criteria

Age8 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Population will be healthy children recruited. All ethnicities will be included and both genders.

You may qualify if:

  • No history of intraocular surgery
  • Best corrected visual acuity (BVCA) 20/25 or better in each eye

You may not qualify if:

  • A spherical refraction outside ± 5.0 D and cylinder correction outside 2.0 D.
  • Intraocular surgery in the study eye
  • History of systemic condition known to affect visual function.
  • History of medication known to affect visual function.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

Study Officials

  • Sylvia Groth, MD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Ophthalmology

Study Record Dates

First Submitted

November 18, 2019

First Posted

November 25, 2019

Study Start

June 15, 2020

Primary Completion

July 1, 2020

Study Completion

December 1, 2022

Last Updated

August 29, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

We are not planning to share individual participant data

Locations